CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP Trial
|<<... 9 10 11 12 13 14 15 16 >>|

Clinical Trial2021 Jan 26;143(4):310-321.

JOURNAL：Circulation. Article Link

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

F Zannad, JP Ferreira, SJ Pocock et al. Keywords: empagliflozin; glomerular filtration rate; heart failure; renal insufficiency; chronic

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top